Healthcare
Xtant Medical Holdings, Inc.(XTNT)
Live Price
Offline$0.44
+0.00% today
1Y Change
-23.88%
Window
Jun 23, 2025 โ Jun 15, 2026
- Market Cap
- $80.00M
- Revenue Growth
- +14.2%
- EPS Growth
- +133.3%
- Dividend Yield
- 0.0%
Coverage: 247 bars ยท Jun 23, 2025 โ Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Xtant Medical Holdings, Inc. (XTNT) is a Healthcare stock with a market cap of $80.00M and listed on AMEX. The stock last traded around $0.44 and down 23.9% across the available one-year price window (Jun 23, 2025 โ Jun 15, 2026). Baseline metrics include revenue growth of +14.2%, EPS growth of +133.3%, a dividend yield of 0.0%. What stands out right now is revenue +14.2%, EPS +133.3%, free cash flow +163.5% with operating margin 5.4% and ROIC 6.5%. Valuation is more restrained than many high-expectation growth names at P/E 15.7 and price/sales 0.6. Stock Foundry combines XTNT price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+14.2% vs +7.6% peer median
Operating Margin
Below sector median
+5.4% vs +19.4% peer median
P/E
Below sector median
15.7 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 12, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +14.2% and EPS at +133.3%, with operating margin around 5.4%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -11.6% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 12, 2026 | โ | -4.8% | -8.8% | -12.8% |
2026 Mar 31, 2026 | +636.7% | -4.6% | -15.7% | -2.4% |
2025 Nov 10, 2025 | +290.5% | -0.6% | -10.2% | -2.8% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
XTNT
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
XTNT Max Drawdown
-53.26%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for XTNT and SPY.
Company Overview
Xtant Medical Holdings, Inc.
New York Stock Exchange American
Xtant Medical Holdings, Inc. develops, manufactures, and markets regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. Its biomaterial products include OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSponge SC that fills bony defects in the subchondral region of joints; OsteoSelect DBM Putty for osteoinductive bone growth; OsteoSelect PLUS DBM Putty for use as a bone void filler and bone graft substitute in the pelvis, extremities, and posterolateral spine; OsteoFactor, which contains various proteins and peptides that support bone formation and remodeling; OsteoWrap; and OsteoVive Plus, a growth factor enriched cellular bone matrix. The company also provides 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone. In addition, it processes and distributes sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications. Further, the company offers Certex spinal fixation, Spider cervical plating, Axle interspinous fusion, Silex Sacroiliac joint fusion, Xpress minimally invasive pedicle screw, and Fortex Pedicle screw systems. Additionally, it provides Calix for cervical and thoracolumbar applications, Axle-X interspinous fusion system, Irix-C cervical integrated fusion system, and Irix-A Lumbar integrated fusion system. The company was formerly known as Bacterin International Holdings, Inc. and changed its name to Xtant Medical Holdings, Inc. in July 2015. Xtant Medical Holdings, Inc. is headquartered in Belgrade, Montana.
- Leadership
- Sean E. Browne
- IPO Date
- Jul 1, 2010
- Employees
- 217
- Street Address
- 664 Cruiser Lane
- Mailing
- Belgrade, MT, 59714
- Region
- Belgrade, MT, US
- Reporting Currency
- USD
- Investor Line
- 406 388 0480
- Last Updated
- May 6, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 15.7
- EV/EBITDA
- 5.7
- Price/Sales
- 0.6
- Price/Book
- 1.5
Growth
- Revenue
- +14.2%
- EPS
- +133.3%
- Free Cash Flow
- +163.5%
Profitability
- Gross Margin
- 62.9%
- Operating Margin
- 5.4%
- Net Margin
- 3.7%
- ROE
- 10.3%
- ROIC
- 6.5%
Balance Sheet
- Debt/Equity
- 0.56
- Current Ratio
- 2.65
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.